 PHILADELPHIA, June 1, 2021 PRNewswire -- Lannett Company, Inc. NYSE: LCI today announced the U.S. Food and Drug Administration FDA has accepted the Abbreviated New Drug Application ANDA for Fluticasone Propionate and Salmeterol inhalation powder 10050 mcg, 25050 mcg and 50050 mcg, which was submitted by Lannett on behalf of its strategic alliance partner, Respirent Pharmaceuticals Co. Ltd. The FDA assigned a Generic Drug User Fee Act of 2017 GDUFA II goal date for this priority original ANDA of January 31, 2022. 